View all cases
UPC APP 11261/2025
—·EP2401365: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Case details
- Status—ActionPreliminary objectionCategoryPreliminary Objection
- Parties
- Respondents
- BioNTech SE
- BioNTech Manufacturing GmbH
- BioNTech Manufacturing Marburg GmbH
- BioNTech Innovative Manufacturing Services GmbH
- BioNTech Europe GmbH
- Pfizer Manufacturing Belgium NV
- Pfizer SAS
- Pfizer AB
- Pfizer, Inc.
Reps: Christine Kanz (Hoyng Rokh Monegier); Tobias J. Hessel (Clifford Chance) - Division
- Munich LD
- Judges
- Andras Kupecz · Judge-rapporteur
- Technology
- Biotechnology
- Language
- —
- First decided
- Apr 17, 2025
Decisions
- 2025-04-17JurisdictionalPreliminary objection
The Local Division Munich ruled on preliminary objections filed by BioNTech and Pfizer entities challenging UPC jurisdiction over Comirnaty COVID-19 vaccine variants sold before 1 June 2023, addressing the UPC's temporal jurisdiction in relation to the opt-out regime and the date of UPC operation.
Legal issues:Preliminary objection – jurisdiction (R.19 RoP)Temporal jurisdiction of UPCOpt-out regimeCOVID-19 vaccine infringement claim
Documents
- 461EA1D1D0D9579BEC10A6A7C20AE019_en.pdf2025-04-17EN